Want to see TLPH full AI Analyst Report?
TLPH Stock Chart & Stats
$1.23
-$0.02(-1.46%)
At close: 4:00 PM EDT
$1.23
-$0.02(-1.46%)
Day’s Range― - ―
52-Week Range$0.69 - $1.57
Previous CloseN/A
Volume89.66K
Average Volume (3M)134.06K
Market Cap
$55.54M
Enterprise Value$67.22M
Total Cash (Recent Filing)$17.08M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Nov 16, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding51,905,796
10 Day Avg. Volume94,111
30 Day Avg. Volume134,063
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)2.84
Price to Sales (P/S)1726.72
P/FCF Ratio-4.25
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue67.22K
Enterprise Value/Gross Profit67.22K
Enterprise Value/Ebitda-4.76
Forecast
1Y Price Target
$3.00Price Target Upside143.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Registrational Trial ProgressNear-complete enrollment and activated sites reduce execution uncertainty around the registrational program. A timely readout could support the targeted PMA filing, creating a defined regulatory path toward a durable hospital-care product.
Clinical And Guideline ValidationIndependent safety review and guideline recognition provide important external validation for nafamostat. These signals can reduce adoption barriers, strengthen credibility with clinicians, and support future commercialization if regulatory requirements are met.
Expanded Addressable MarketA larger projected procedure base increases the potential market available to a successful product launch. The 21% estimate increase improves the commercial opportunity and provides more room for durable revenue growth after approval.
Bears Say
Minimal Revenue And Persistent LossesThe company has not yet established a revenue base capable of supporting its cost structure. Continued large losses leave future earnings dependent on successful commercialization, making the business financially fragile until product revenue scales.
Cash Burn And Financing DependencePersistent operating cash outflows require Talphera to secure outside capital while advancing its pipeline. Conditional financing creates execution risk because delays or unmet conditions could reduce runway before key clinical and regulatory milestones.
Regulatory And Adoption Timing RiskCommercialization remains exposed to uncertain trial, FDA, and approval timing, which can defer revenue generation. A non-first-line guideline position may also slow initial adoption even if the product receives regulatory clearance.
Talphera News
TLPH FAQ
What was Talphera’s price range in the past 12 months?
Talphera lowest stock price was $0.69 and its highest was $1.57 in the past 12 months.
What is Talphera’s market cap?
Talphera’s market cap is $55.54M.
When is Talphera’s upcoming earnings report date?
Talphera’s upcoming earnings report date is Nov 16, 2026 which is in 25 days.
How were Talphera’s earnings last quarter?
Talphera released its earnings results on Aug 12, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.062 by $0.002.
Is Talphera overvalued?
According to Wall Street analysts Talphera’s price is currently Undervalued.
Does Talphera pay dividends?
Talphera does not currently pay dividends.
What is Talphera’s EPS estimate?
Talphera’s EPS estimate is -0.05.
How many shares outstanding does Talphera have?
Talphera has 51,905,796 shares outstanding.
What happened to Talphera’s price movement after its last earnings report?
Talphera reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.062. Following the earnings report the stock price went down -13.571%.
Which hedge fund is a major shareholder of Talphera?
Currently, no hedge funds are holding shares in TLPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Talphera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (143.90% Upside)
$3.00 (143.90% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.95%
12-Months-Change
Fundamentals
Return on Equity
-87.28%
Trailing 12-Months
Asset Growth
62.31%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Talphera
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
TLPH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents strong clinical and commercial momentum: 75% enrollment in a registrational trial, positive DSMB feedback, KDIGO recognition of nafamostat, expanded market sizing (+21%), and encouraging dosing/titration data. Financially the company has runway assumptions but relies on conditional financing (~$16M) and faces modest near-term expense increases and regulatory timing uncertainty. On balance the achievements and favorable clinical/commercial signals outweigh the financing and timing risks.View all TLPH earnings summariesTLPH Stock 12 Month Forecast
Average Price Target
$3.00
▲(143.90% Upside)
Technical Analysis
Sonoma Pharmaceuticals
―
Perrigo Company
―
Organogenesis Holdings
―
Evolus
―
Journey Medical Corp
―
Ownership Overview
6.01% Insiders
1.48% Mutual Funds
0.57% Other Institutional Investors
90.02% Public Companies and
Individual Investors